Hah Jennifer M, Hilmoe Heather, Schmidt Peter, McCue Rebecca, Trafton Jodie, Clay Debra, Sharifzadeh Yasamin, Ruchelli Gabriela, Hernandez Boussard Tina, Goodman Stuart, Huddleston James, Maloney William J, Dirbas Frederick M, Shrager Joseph, Costouros John G, Curtin Catherine, Mackey Sean C, Carroll Ian
Division of Pain Medicine, Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, USA.
Stanford Systems Neuroscience and Pain Lab, Stanford University, Stanford, CA, USA.
J Pain Res. 2020 Nov 18;13:2959-2970. doi: 10.2147/JPR.S269370. eCollection 2020.
Preoperative patient-specific risk factors may elucidate the mechanisms leading to the persistence of pain and opioid use after surgery. This study aimed to determine whether similar or discordant preoperative factors were associated with the duration of postoperative pain and opioid use.
In this post hoc analysis of a randomized, double-blind, placebo-controlled trial of perioperative gabapentin vs active placebo, 410 patients aged 18-75 years, undergoing diverse operations underwent preoperative assessments of pain, opioid use, substance use, and psychosocial variables. After surgery, a modified Brief Pain Inventory was administered over the phone daily up to 3 months, weekly up to 6 months, and monthly up to 2 years after surgery. Pain and opioid cessation were defined as the first of 5 consecutive days of 0 out of 10 pain or no opioid use, respectively.
Overall, 36.1%, 19.8%, and 9.5% of patients continued to report pain, and 9.5%, 2.4%, and 1.7% reported continued opioid use at 3, 6, and 12 months after surgery. Preoperative pain at the future surgical site (every 1-point increase in the Numeric Pain Rating Scale; HR 0.93; 95% CI 0.87-1.00; =0.034), trait anxiety (every 10-point increase in the Trait Anxiety Inventory; HR 0.79; 95% CI 0.68-0.92; =0.002), and a history of delayed recovery after injury (HR 0.62; 95% CI 0.40-0.96; =0.034) were associated with delayed pain cessation. Preoperative opioid use (HR 0.60; 95% CI 0.39-0.92; =0.020), elevated depressive symptoms (every 5-point increase in the Beck Depression Inventory-II score; HR 0.88; 95% CI 0.80-0.98; =0.017), and preoperative pain outside of the surgical site (HR 0.94; 95% CI 0.89-1.00; =0.046) were associated with delayed opioid cessation, while perioperative gabapentin promoted opioid cessation (HR 1.37; 95% CI 1.06-1.77; =0.016).
Separate risk factors for prolonged post-surgical pain and opioid use indicate that preoperative risk stratification for each outcome may identify patients needing personalized care to augment universal protocols for perioperative pain management and conservative opioid prescribing to improve long-term outcomes.
术前患者特异性风险因素可能有助于阐明术后疼痛持续和阿片类药物使用的机制。本研究旨在确定相似或不一致的术前因素是否与术后疼痛持续时间和阿片类药物使用有关。
在这项围手术期加巴喷丁与活性安慰剂的随机、双盲、安慰剂对照试验的事后分析中,410例年龄在18 - 75岁、接受各种手术的患者接受了术前疼痛、阿片类药物使用、物质使用和社会心理变量的评估。术后,通过电话每天进行改良简短疼痛问卷评估,持续至术后3个月,每周评估至6个月,每月评估至2年。疼痛停止和阿片类药物停用分别定义为连续5天疼痛评分为0分或未使用阿片类药物的第一天。
总体而言,术后3个月、6个月和12个月时,分别有36.1%、19.8%和9.5%的患者持续报告疼痛,9.5%、2.4%和1.7%的患者报告持续使用阿片类药物。未来手术部位的术前疼痛(数字疼痛评分量表每增加1分;风险比0.93;95%置信区间0.87 - 1.00;P = 0.034)、特质焦虑(特质焦虑量表每增加10分;风险比0.79;95%置信区间0.68 - 0.92;P = 0.002)以及损伤后恢复延迟史(风险比0.62;95%置信区间0.40 - 0.96;P = 0.034)与疼痛停止延迟相关。术前阿片类药物使用(风险比0.60;95%置信区间0.39 - 0.92;P = 0.020)、抑郁症状加重(贝克抑郁量表-II评分每增加5分;风险比0.88;置信区间0.80 - 0.98;P = 0.017)以及手术部位以外的术前疼痛(风险比0.94;95%置信区间0.89 - 1.00;P = 0.046)与阿片类药物停用延迟相关,而围手术期加巴喷丁可促进阿片类药物停用(风险比1.37;95%置信区间1.06 - 1.77;P = 0.016)。
术后疼痛延长和阿片类药物使用的独立风险因素表明,对每个结局进行术前风险分层可能识别出需要个性化护理的患者,以加强围手术期疼痛管理的通用方案和保守的阿片类药物处方,从而改善长期结局。